Clinical Trial Search

Primary: Time to Readiness for Discharge From Hospital — 87.78; 93.47 Hours — p=0.7944

Primary: Number of Participants With Metabolic Syndrome After 6 Months of Treatment Metformin or OCP+Metformin for 6 Months. — 17; 17; 18 Participants

Primary: Percentage of Participants Achieving Sustained Remission at Week 52 — 29.0; 41.1; 46.4 percentage of participants — p==0.0019

Primary: Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) — 1990; 1970; 41; 33 Participants — p=<0.001

Primary: Percent Change From Baseline in Fasting TG at Month 6 — 11.52; -10.85; -31.99 percent change — p==0.0009

Primary: Time-Normalized Investigator-Confirmed (IC) HAE Attack Rate (Per Month) From Week 1 to Week 25 — 2.26; 0.44; 1.02 HAE attacks per month — p=<0.001

Primary: Lean Body Mass as Measured by Dual Energy X-Ray Absorptiometry (DEXA) at Baseline — 49.9; 49.6 kilograms

Primary: Progression Free-survival — 9.4; 5.2 months — p=0.0001

Primary: Number of Participants With Solicited Local Adverse Events (AEs) After the Vaccination With rMenB+OMV NZ — 12; 12; 14; 22 Participants

Primary: Compare Effectiveness in Curbing Transmission of Leprosy of Three Different Approaches of Post Exposure Prophylaxis — 1.04; 1.42; 0.98; 0.92 number of new cases per 1000…

Primary: Efficacy Endpoint: First Occurrence of Reverse Transcription-polymerase Chain Reaction (RT-PCR) Confirmed Influenza, Due to Any Influenza Type A and/or B Virus…

Primary: Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state) — -0.10; 0.57; -0.04 units on a scale

Primary: Number of Participants With Solicited Local and Systemic ARs — 270; 554; 113; 290 Participants

Primary: Percent Change in Volume of Alveolar Ridge as Measured by 3D Intraoral Scanning — 15.5; 16.8 percentage of volume change

Primary: Efficacy - Primary Endpoint During the Blinded Period — 78.7; 4.8 Percentage of participants — p=<0.0001